Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARABELA Study
2024-514395-40-00Phase 2Authorised
- Sponsor
- GEICAM
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abemaciclib and letrozole in breast cancer (2 arms), sponsored by GEICAM. Primary endpoint: Residual Cancer Burden (RCB) 0-I rate. Planned start Oct 2024; status: authorised.
02
Drugs
abemaciclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-514395-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514395-40-00.